EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel topical immunomodulatory therapy for psoriasis: bridging the therapeutic gap in moderate disease

Thong Teck Tan, Kok Hian Tan, Sai Kiang Lim

Extracellular Vesicles and Circulating Nucleic Acids · 24.04.2026 · 7 (2) · 580-94

DOI: 10.20517/evcna.2025.150 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Extracellular Vesicles and Circulating Nucleic Acids, online erschienen am 24.04.2026. Verfasst von Thong Teck Tan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Paracrine Therapeutics Pte. Ltd., Singapore 536464, Singapore. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic, immune-mediated inflammatory disease that affects approximately 2%-3% of the global population, and remains a major dermatologic and psychosocial burden. Despite advances in biologics targeting interleukin 17 (IL-17) and interleukin 23 (IL-23) pathways, effective and accessible treatment options for moderate psoriasis are lacking. Topical therapies and phototherapy are often inadequate, while systemic agents and biologics are limited by toxicity, high cost, and restricted reimbursement criteria, leaving patients with moderate disease without adequate therapeutic options. Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) have emerged as a promising acellular therapeutic modality that harnesses the immunomodulatory and regenerative properties of parent MSCs. Unlike systemic biologics, MSC-EVs act locally and non-immunosuppressively. Topically applied MSC-EVs have demonstrated the ability to modulate cutaneous inflammation by attenuating complement activation [via CD59-mediated inhibition of complement terminal component 5b-9 (C5b-9) complex formation], reducing neutrophil infiltration, and subsequently lowering IL-17 and IL-23 expression in psoriatic lesions. Preclinical and early clinical studies suggest that MSC-EVs can restore local immune homeostasis through paracrine extracellular mechanisms, without systemic absorption or adverse effects. MSC-EVs represent a new class of cell-free nanotherapeutics inspired by biologics, capable of localized immunomodulation in psoriasis. By combining biologic-like efficacy with the safety and accessibility of topical therapy, MSC-EVs may bridge the long-standing therapeutic gap in moderate psoriasis. This review discusses current treatment limitations, the mechanistic rationale for MSC-EVs in psoriatic inflammation, and their potential to redefine dermatologic immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

IL-17Psoriasiscell-free therapeuticscomplement systemextracellular vesiclesimmunomodulationmesenchymal stromal cellstopical therapy

Autor:innen und Institutionen

  • Paracrine Therapeutics Pte. Ltd., Singapore 536464, Singapore.
  • Division of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore 229899, Singapore.
  • Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.

Zitieren

APA

Tan, T. T., Tan, K. H., & Lim, S. K. (2026). Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel topical immunomodulatory therapy for psoriasis: bridging the therapeutic gap in moderate disease. Extracellular Vesicles and Circulating Nucleic Acids, 7(2), 580-94. https://doi.org/10.20517/evcna.2025.150

Vancouver

Tan TT, Tan KH, Lim SK. Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel topical immunomodulatory therapy for psoriasis: bridging the therapeutic gap in moderate disease. Extracellular Vesicles and Circulating Nucleic Acids. 2026;7(2):580-94. doi:10.20517/evcna.2025.150

BibTeX
@article{Tan2026,
  author = {Tan, Thong Teck and Tan, Kok Hian and Lim, Sai Kiang},
  title = {Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel topical immunomodulatory therapy for psoriasis: bridging the therapeutic gap in moderate disease},
  journal = {Extracellular Vesicles and Circulating Nucleic Acids},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {580--94},
  doi = {10.20517/evcna.2025.150}
}
Kostenlos starten →